首页> 中文期刊> 《药学学报:英文版》 >Designing the new generation of intelligent biocompatible carriers for protein and peptide delivery

Designing the new generation of intelligent biocompatible carriers for protein and peptide delivery

         

摘要

Therapeutic proteins and peptides have revolutionized treatment for a number of diseases, and the expected increase in macromolecule-based therapies brings a new set of challenges for the pharmaceutics field. Due to their poor stability, large molecular weight, and poor transport properties,therapeutic proteins and peptides are predominantly limited to parenteral administration. The short serum half-lives typically require frequent injections to maintain an effective dose, and patient compliance is a growing issue as therapeutic protein treatments become more widely available. A number of studies have underscored the relationship of subcutaneous injections with patient non-adherence, estimating that over half of insulin-dependent adults intentionally skip injections. The development of oral formulations has the potential to address some issues associated with non-adherence including the interference with daily activities, embarrassment, and injection pain. Oral delivery can also help to eliminate the adverse effects and scar tissue buildup associated with repeated injections. However, there are several major challenges associated with oral delivery of proteins and peptides, such as the instability in the gastrointestinal(GI)tract, low permeability, and a narrow absorption window in the intestine. This review provides a detailed overview of the oral delivery route and associated challenges. Recent advances in formulation and drugdelivery technologies to enhance bioavailability are discussed, including the co-administration of compounds to alter conditions in the GI tract, the modification of the macromolecule physicochemical properties, and the use of improved targeted and controlled release carriers.

著录项

  • 来源
    《药学学报:英文版》 |2018年第2期|P.147-164|共18页
  • 作者单位

    McKetta Department of Chemical Engineering, The University of Texas at Austin;

    Institute for Biomaterials, Drug Delivery, and Regenerative Medicine, The University of Texas at Austin;

    Department of Biomedical Engineering, The University of Texas at Austin;

    Department of Pediatrics, Dell Medical School, The University of Texas at Austin;

    Department of Surgery and Perioperative Care, Dell Medical School, The University of Texas at Austin;

    Division of Pharmaceutics, College of Pharmacy, The University of Texas at Austin;

    McKetta Department of Chemical Engineering, The University of Texas at Austin;

    Institute for Biomaterials, Drug Delivery, and Regenerative Medicine, The University of Texas at Austin;

    Department of Biomedical Engineering, The University of Texas at Austin;

    Department of Pediatrics, Dell Medical School, The University of Texas at Austin;

    Department of Surgery and Perioperative Care, Dell Medical School, The University of Texas at Austin;

    Division of Pharmaceutics, College of Pharmacy, The University of Texas at Austin;

    McKetta Department of Chemical Engineering, The University of Texas at Austin;

    Institute for Biomaterials, Drug Delivery, and Regenerative Medicine, The University of Texas at Austin;

    Department of Biomedical Engineering, The University of Texas at Austin;

    Department of Pediatrics, Dell Medical School, The University of Texas at Austin;

    Department of Surgery and Perioperative Care, Dell Medical School, The University of Texas at Austin;

    Division of Pharmaceutics, College of Pharmacy, The University of Texas at Austin;

  • 原文格式 PDF
  • 正文语种 CHI
  • 中图分类 制剂学;
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号